首页 | 本学科首页   官方微博 | 高级检索  
     

利格列汀联合地特胰岛素治疗2型糖尿病临床效果及安全性分析
引用本文:李伟. 利格列汀联合地特胰岛素治疗2型糖尿病临床效果及安全性分析[J]. 糖尿病新世界, 2021, 0(3): 97-99
作者姓名:李伟
作者单位:郯城县第一人民医院内分泌科
摘    要:目的 分析利格列汀联合地特胰岛素治疗2型糖尿病临床效果及安全性情况.方法 选择2019年8月—2020年8月该院收治80例2型糖尿病患者,按随机数表分为两组,对照组40例使用地特胰岛素治疗,研究组40例使用利格列汀联合地特胰岛素治疗,分析两组患者效果、不良反应、血糖指标与生活质量.结果 研究组患者显效40.00%,对照...

关 键 词:利格列汀  地特胰岛素  2型糖尿病  临床效果  安全性

Clinical Effect and Safety Analysis of Linagliptin Combined with Insulin Detemir in the Treatment of Type 2 Diabetes
LI Wei. Clinical Effect and Safety Analysis of Linagliptin Combined with Insulin Detemir in the Treatment of Type 2 Diabetes[J]. Diabetes New World, 2021, 0(3): 97-99
Authors:LI Wei
Affiliation:(Department of Endocrinology,the First People's Hospital of Tancheng County,Linyi,Shandong Province,276100 China)
Abstract:Objective To analyze the clinical effect and safety of linagliptin combined with insulin detemir in the treatment of type 2 diabetes.Methods From August 2019 to August 2020,80 patients with type 2 diabetes were selected and divided into two groups according to the random number table.40 patients in the control group were treated with insulin detemir and 40 patients in the study group were treated with linagliptin combined with insulin detemir,the effects,adverse reactions,blood glucose indicators and quality of life of the two groups of patients were analyzed.Results The patients in the study group were markedly effective 40.00%,and the control group was markedly effective 32.50%.The total clinical effectiveness of the study group was 90.00%higher than that of the control group 70.00%,the difference was statistically significant(P<0.05);the fasting blood glucose after treatment in the study group(6.62±1.25)mmol/L,2 h postprandial the blood glucose(9.55±1.46)mmol/L and glycosylated hemoglobin index(6.21±0.40)%at 2 h after meal were lower than those of the control group,and the difference was statistically significant(P<0.05);adverse reactions such as hypoglycemia,fatigue and abdominal distension in the study group was lower than that of the control group,and the difference was statistically significant(P<0.05);the quality of life(89.17±8.25)points of the study group was higher than that of the control group(76.50±10.42)points,and the difference was statistically significant(P<0.05).Conclusion The combined treatment of linagliptin and insulin detemir for type 2 diabetes can reduce blood glucose levels and adverse reactions,improve the efficacy and quality of life of patients,and has certain clinical application value.
Keywords:Linagliptin  Insulin detemir  Type 2 diabetes  Clinical effects  Safety
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号